Evaluation of Metal‐Organic Framework MIL-89 nanoparticles toxicity on embryonic zebrafish development

Al-Ansari, Dana E.; Al-Badr, Mashael Ali H I; Zakaria, Zain Zaki; Mohamed, Nura A.; Nasrallah, Gheyath K.; Yalcin, Huseyin C.; Abou-Saleh, Haissam

doi:10.1016/j.toxrep.2022.04.016

Cited by 8 publications

(8 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The optical transparency of embryos allows easy visualization of organ morphology and possible malformations, thus avoiding invasive techniques [ 74 , 75 , 76 ]. Some recent studies have highlighted the importance of this kind of model to test nanoparticle toxicity [ 73 , 77 , 78 , 79 , 80 , 81 ].…”

Section: Resultsmentioning

confidence: 99%

Evidence That a Peptide-Drug/p53 Gene Complex Promotes Cognate Gene Expression and Inhibits the Viability of Glioblastoma Cells

Neves,

Albuquerque,

Faria

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Glioblastoma multiform (GBM) is considered the deadliest brain cancer. Conventional therapies are followed by poor patient survival outcomes, so novel and more efficacious therapeutic strategies are imperative to tackle this scourge. Gene therapy has emerged as an exciting and innovative tool in cancer therapy. Its combination with chemotherapy has significantly improved therapeutic outcomes. In line with this, our team has developed temozolomide–transferrin (Tf) peptide (WRAP5)/p53 gene nanometric complexes that were revealed to be biocompatible with non-cancerous cells and in a zebrafish model and were able to efficiently target and internalize into SNB19 and U373 glioma cell lines. The transfection of these cells, mediated by the formulated peptide-drug/gene complexes, resulted in p53 expression. The combined action of the anticancer drug with p53 supplementation in cancer cells enhances cytotoxicity, which was correlated to apoptosis activation through quantification of caspase-3 activity. In addition, increased caspase-9 levels revealed that the intrinsic or mitochondrial pathway of apoptosis was implicated. This assumption was further evidenced by the presence, in glioma cells, of Bax protein overexpression—a core regulator of this apoptotic pathway. Our findings demonstrated the great potential of peptide TMZ/p53 co-delivery complexes for cellular transfection, p53 expression, and apoptosis induction, holding promising therapeutic value toward glioblastoma.

show abstract

Section: Resultsmentioning

confidence: 99%

Evidence That a Peptide-Drug/p53 Gene Complex Promotes Cognate Gene Expression and Inhibits the Viability of Glioblastoma Cells

Neves,

Albuquerque,

Faria

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Given the complete toxicity evaluation of Fe-MOF, Al-Ansari et al and Chen et al studied the toxicity of MIL-89 and MIL-100(Fe) in vivo ( Figure 4C and D ). 44 , 47 As indicated by all the parameters studied (eg, serum, enzymology, and histology), MIL-89 had no acute or subacute toxicity symptoms, and its degradation and excretion mechanism was believed to be that nano-Fe-MOFs particles were rapidly isolated by liver and spleen, and then further biodegradable and directly eliminated in urine or stool, without metabolic and substantive toxicity. 44 Within a safe dose of 80 μg/mL, MIL-100(Fe) particles had excellent biocompatibility with human normal liver cells (HL-7702) and hepatocellular carcinoma cells (HepG2), low cytotoxicity, and allowed a high cell survival rate.…”

Section: Key Indicators Of Fe-mofs Materials In Biomedical Applicationsmentioning

confidence: 97%

“…The evaluation of biological toxicity mainly comprises (i) the initial toxicity evaluation of the cations and ligands that make up the MOFs materials using LD50 (half lethal dose parameter), 42 (ii) the test of the cytotoxicity of MOFs to gain insights into the cytotoxicity at the cell level, 43 (iii) toxicity research in vivo, which is the critical test since it presents the most direct and valuable information. 44 …”

Section: Key Indicators Of Fe-mofs Materials In Biomedical Applicationsmentioning

confidence: 99%

See 1 more Smart Citation

Application and Development Prospect of Nanoscale Iron Based Metal-Organic Frameworks in Biomedicine

Peng,

Xu,

Zeng

et al. 2023

IJN

View full text Add to dashboard Cite

Metal-organic frameworks (MOFs) are coordination polymers that comprise metal ions/clusters and organic ligands. MOFs have been extensively employed in different fields (eg, gas adsorption, energy storage, chemical separation, catalysis, and sensing) for their versatility, high porosity, and adjustable geometry. To be specific, Fe 2+ /Fe 3+ exhibits unique redox chemistry, photochemical and electrical properties, as well as catalytic activity. Fe-based MOFs have been widely investigated in numerous biomedical fields over the past few years. In this study, the key index requirements of Fe-MOF materials in the biomedical field are summarized, and a conclusion is drawn in terms of the latest application progress, development prospects, and future challenges of Fe-based MOFs as drug delivery systems, antibacterial therapeutics, biocatalysts, imaging agents, and biosensors in the biomedical field.

show abstract

“…MIL-100 and trimesic acid were administered intravenously at doses of approximately 220 mg/kg and 78 mg/kg, respectively, and the study revealed that weight growth and the animal behavior of treated rats were completely normal when matched with the group that served as the control. This led to the conclusion that the concerned ingredient is suitable for drug delivery [ 165 ].…”

Section: Challenge Of Mof Nanomaterials In Cancer Treatmentmentioning

confidence: 99%

Utilization of Functionalized Metal–Organic Framework Nanoparticle as Targeted Drug Delivery System for Cancer Therapy

Tran

Doan

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Cancer is a multifaceted disease that results from the complex interaction between genetic and environmental factors. Cancer is a mortal disease with the biggest clinical, societal, and economic burden. Research on better methods of the detection, diagnosis, and treatment of cancer is crucial. Recent advancements in material science have led to the development of metal–organic frameworks, also known as MOFs. MOFs have recently been established as promising and adaptable delivery platforms and target vehicles for cancer therapy. These MOFs have been constructed in a fashion that offers them the capability of drug release that is stimuli-responsive. This feature has the potential to be exploited for cancer therapy that is externally led. This review presents an in-depth summary of the research that has been conducted to date in the field of MOF-based nanoplatforms for cancer therapeutics.

show abstract

Evaluation of Metal‐Organic Framework MIL-89 nanoparticles toxicity on embryonic zebrafish development

Cited by 8 publications

References 72 publications

Evidence That a Peptide-Drug/p53 Gene Complex Promotes Cognate Gene Expression and Inhibits the Viability of Glioblastoma Cells

Evidence That a Peptide-Drug/p53 Gene Complex Promotes Cognate Gene Expression and Inhibits the Viability of Glioblastoma Cells

Application and Development Prospect of Nanoscale Iron Based Metal-Organic Frameworks in Biomedicine

Utilization of Functionalized Metal–Organic Framework Nanoparticle as Targeted Drug Delivery System for Cancer Therapy

Contact Info

Product

Resources

About